BioLine Rx Posts $1.2M 2025 Revenues and $21M Cash, GBM Trial Update
Revenues plunged to $1.2 million in 2025 from $28.9 million in 2024, while a $21 million cash balance funds operations into mid-2027. The Phase 1 GBM study will assess safety and dose escalation as primary endpoints, with efficacy data as a secondary outcome and no interim readouts planned.
1. 2025 Financial Performance
Revenues fell to $1.2 million in 2025 from $28.9 million in 2024, driven by reduced milestone payments. A cash balance of $21 million is expected to fund operations through the first half of 2027.
2. GLIX1 GBM Phase 1 Study Design
The Phase 1 trial focuses on dose escalation to establish safety and recommended dose in glioblastoma multiforme, with efficacy as a secondary endpoint. No interim efficacy readouts are planned while patient biopsies are optional and not required for blood-brain barrier assessment.
3. APHEXDA Sales Guidance Uncertainty
Long-term sales projections for APHEXDA remain unclear as partner Ayrmid has not provided guidance. Ongoing discussions may yield forecasts, but no projections are expected in the near term.
4. Gloria Bridging Trial Progress
Gloria has addressed most financial constraints and initiated a Phase 3 bridging study in stem cell mobilization for China approval. The trial is blinded with data anticipated by mid-2027 and no interim readouts planned.